Get started
Author

Sarah E. Biehn

Observed names: S. Biehn, Sarah E Biehn
ORCID: 0000-0001-9712-4621
Observed ORCID: 0000-0001-9712-4621
OpenAlex ID: A5030287810
Accurate protein structure prediction with hydroxyl radical protein footprinting data
2021 · Sarah E. Biehn, Steffen Lindert · Nature Communications · 45
PDF
Protein Structure Prediction with Mass Spectrometry Data
2021 · Sarah E. Biehn, Steffen Lindert · Annual Review of Physical Chemistry · 33
PDF
Utilization of Hydrophobic Microenvironment Sensitivity in Diethylpyrocarbonate Labeling for Protein Structure Prediction
2021 · Sarah E. Biehn, Patanachai Limpikirati, et al. · Analytical Chemistry · 31
Validated determination of NRG1 Ig-like domain structure by mass spectrometry coupled with computational modeling
2022 · Niloofar Abolhasani Khaje, Alexander Eletsky, et al. · Communications Biology · 15
PDF
Accounting for Neighboring Residue Hydrophobicity in Diethylpyrocarbonate Labeling Mass Spectrometry Improves Rosetta Protein Structure Prediction
2022 · Sarah E. Biehn, Danielle M. Picarello, et al. · Journal of the American Society for Mass Spectrometry · 14
BioPrint Meets the AI Age: Development of Artificial Intelligence-Based ADMET Models for the Drug-Discovery Platform SAFIRE
2024 · Sarah E Biehn, Luis Miguel Goncalves, et al. · Future Medicinal Chemistry · 10
Small Molecule Inhibitors Targeting Transgelin-2-Actin Interaction for Therapeutic Intervention in Glioblastoma
2022 · A. Kumar, P. Rajasekera, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3β Pathway in Glioblastoma
2023 · A. Kumar, P. Rajasekera, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
PDF
OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target Liabilities
2026 · Sarah E. Biehn, Juerg Lehmann, et al. · Pharmaceuticals
PDF
Biochemical and Biophysical Studies of Novel Small Molecules Targeting Proteasome Subunit Alpha Type-7 (PSMA7) for the Treatment of Glioblastoma
2024 · C.A. Showalter, P. Rajasekera, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
2040: Targeting Transgelin-2 overcomes treatment resistance by downregulating PI3K/AKT pathway in GBM
2024 · Ashok Kumar, Priyani V. Rajasekara, et al. · Radiotherapy and Oncology
In Silico Discovery and Investigation of Novel Small Molecules Targeting PSMA7 for the Treatment of GBM
2023 · C.A. Showalter, P. Rajasekera, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
PO-1145 Targeting Transgelin-2 by novel small molecule inhibitors to circumvent resistance in glioblastoma
2023 · A. Kumar, P. Rajasekera, et al. · Radiotherapy and Oncology
In-Silico Discovery of Novel Small-Molecule Inhibitors Targeting Transgelin-2-Actin Interaction Inhibits Proliferation, Invasion and Improves Chemo-Radiation Response in Human Glioblastoma
2021 · A. Kumar, P. Rajasekera, et al. · International Journal of Radiation Oncology*Biology*Physics
Pharmacological Targeting Of Transgelin-2 As A Novel Strategy Of Therapeutic Intervention In Glioblastoma
2020 · A. Kumar, P. Rajasekera, et al. · International Journal of Radiation Oncology*Biology*Physics
Works count: 15
Citation count: 151
H-index: 6
I10-index: 6
Year
Topic
Type